MindMed's recent financing has closed after being upsized all the way to CAD$34.5 million.
MindMed's recent financing has closed after being upsized all the way to CAD$34.5 million.
Entheon has secured a supply of DMT for delivery to its drug research center (CHDR) in the Netherlands.
Champignon Brands names an interim CFO after Stephen Brohman resigns.
Mydecine completes its first commercial harvest of 20 kilograms of psilocybin mushrooms.
Mind Cure's initial R&D focus will be on psilocybin, ketamine and ibogaine. Researching both pain and mental health applications for psychedelics.
Cybin Corp acquires Adelia Therapeutics in an all-stock transaction valued at CAD$20.2 million.
Numinus announces a bought deal financing at CAD$0.68 cents.
Entheon discusses its new strategic investment in Wonder Scientific.
Numinus' Vancouver clinic will be used for collaboration on a clinical trial with MAPS for MDMA-assisted therapy for PTSD.
Mind Cure stock is now much more easily accessible for U.S.-based investors.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now